Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial

Table 1 Study assessment measures

Assessment measures	Preoperation	Postoperative day 5	One month after surgery	Two months after surgery	Three months after surgery	Six months after surgery	Every six months until HCC recurrence /metastasis or death
Blood routine examination	x	x	x	x	x	x	x
Urine routines	x	x	x	x	x	x	x
Stool routine examination	x	x	x	x	x	x	x
Liver function	x	x	x	x	x	x	x
Renal function	x	x	x	x	x	x	x
Myocardial enzyme	x	x	x	x	x	x	x
Hepatitis B virological test¹	x		x	x	x	x	x
Coagulation function	x	x	x	x	x	x	x
Lipid level²	x		x	x	x	x	x
Alpha fetoprotein	x		x	x	x	x	x
Des-gamma-carboxy prothrombin	x		x	x	x	x	x
Hepatits C antibody	x
Human immunodeficiency virus antibody	x
• Blood HCG test³	x
Electrocardiogram	x		x	x	x	x	x
Abdominal ultrasonography	x		x	x	x	x	x
Chest and upper abdomen enhanced MRI/CT	x		x	x	x	x	x

CT Computed tomography, HCC Hepatocellular carcinoma, MRI Magnetic resonance imaging, RFS Recurrence-free survival, OS Overall survival
1. Including hepatits B surface antigen, hepatits B surface antibody, hepatits B e antigen, hepatits B e antibody, hepatits B c antibody, and hepatits B virus DNA
2. Including triglyceride, cholesterol, high-density lipoprotein, and low-density lipoprotein
3. Women of childbearing age

ISSN: 1745-6215